We assessed the prognostic value of minimal residual disease (MRD) within the ML17638 phase 3 trial from the Fondazione Italiana Linfomi, investigating the role of rituximab maintenance in elderly follicular lymphoma (FL) patients after a brief first-line chemoimmunotherapy. MRD for the bcl-2/IgH translocation was determined on bonemarrowcells in a centralized laboratory belonging to the Euro-MRD consortium, using qualitative and quantitative polymerase chain reactions (PCRs). Of 234 enrolled patients, 227 (97%) were screened at diagnosis. A molecular marker (MM) was found in 51%. Patients with an MM were monitored at 8 subsequent times. Of the 675 expected follow-up samples, 83% were analyzed. Conversion to PCR negativity predicted better progression-free survival (PFS) at all post-treatment times (eg, end of therapy: 3-year PFS, 72% vs 39%; P < .007). MRD was predictive in both maintenance (83% vs 60%; P < .007) and observation (71% vs 50%; P < .001) groups. PCR positivity at the end of induction was an independent adverse predictor (hazard ratio, 3.1; 95% confidence interval, 1.36-7.07). MRD is a powerful independent outcome predictor in FL patients who receive rituximab-intensive programs, suggesting a need to investigate its value for decision-making. This trial was registered at www.clinicaltrial.gov as #NCT01144364. © 2013 by The American Society of Hematology.

Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program / Marco, Ladetto; Chiara, Lobetti-Bodoni; Barbara, Mantoan; Manuela, Ceccarelli; Carola, Boccomini; Elisa, Genuardi; Annalisa, Chiappella; Baldini, Luca; Giuseppe, Rossi; Alessandro, Pulsoni; Francesco Di Raimondo, ; Luigi, Rigacci; Antonello, Pinto; Sara, Galimberti; Bari, Alessia; Delia, Rota-Scalabrini; Angela, Ferrari; Francesco, Zaja; Andrea, Gallamini; Giorgina, Specchia; Pellegrino, Musto; Francesca Gaia Rossi, ; Enrica, Gamba; Andrea Evangelista and Umberto Vitolo for the Fondazione Italiana Linfomi, ; Collaborators: Lobetti-Bodoni, C; Mantoan, B; Genuardi, E; Boccadoro, M; Ladetto, M; Ciccone, G; Evangelista, A; Ceccarelli, M; Boccomini, C; Chiappella, A; Botto, B; Orsucci, L; Vitolo, U; Goldaniga, M; Rossi, Fg; Baldini, L; Bottelli, C; Tucci, Angelo Carmelo; Rossi, G; Pulsoni, A; De Angelis, F; RUSSO ERMOLLI, Elda; Martelli, M; Foà, R; Di Raimondo, F; Chiarenza, Antonino; Rigacci, L; Puccini, B; Bosi, A; Pinto, Alessandra; Petrini, Marino; Galimberti, S; Bari, A; Sacchi, S; Federico, M; Rota-Scalabrini, D; Aglietta, M; Ferrari, A; Alvarez De Celis, I; Merli, F; Zaja, F; Fanin, R; Castellino, C; Gallamini, A; Parvis, G; Saglio, G; Perrone, T; Specchia, G; Musto, P; Gamba, E; Corradini, P; Pogliani, Em; Liberati, Am; Leone, G; Patti, C; Fioritoni, G; Rusconi, C; Morra, E; Tonso, A; Cabras, G; Angelucci, E; Rossi, A; Rambaldi, A; Cortelazzo, S; Morandi, S; Lanza, F; Pizzolo, G; Amadori, S; Zinzani, Pl; Stelitano, C; Nobile, F. - In: BLOOD. - ISSN 0006-4971. - 122:23(2013), pp. 3759-3766. [10.1182/blood-2013-06-507319]

Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program

Luca Baldini
Membro del Collaboration Group
;
Alessia Bari;Baldini L;TUCCI, Angelo Carmelo
Membro del Collaboration Group
;
RUSSO ERMOLLI, ELDA
Membro del Collaboration Group
;
CHIARENZA, ANTONINO
Membro del Collaboration Group
;
PINTO, ALESSANDRA
Membro del Collaboration Group
;
PETRINI, Marino
Membro del Collaboration Group
;
Bari A
Membro del Collaboration Group
;
Sacchi S
Membro del Collaboration Group
;
Federico M;Aglietta M
Membro del Collaboration Group
;
Merli F
Membro del Collaboration Group
;
Corradini P
Membro del Collaboration Group
;
Liberati AM
Membro del Collaboration Group
;
Patti C
Membro del Collaboration Group
;
Morandi S
Membro del Collaboration Group
;
2013

Abstract

We assessed the prognostic value of minimal residual disease (MRD) within the ML17638 phase 3 trial from the Fondazione Italiana Linfomi, investigating the role of rituximab maintenance in elderly follicular lymphoma (FL) patients after a brief first-line chemoimmunotherapy. MRD for the bcl-2/IgH translocation was determined on bonemarrowcells in a centralized laboratory belonging to the Euro-MRD consortium, using qualitative and quantitative polymerase chain reactions (PCRs). Of 234 enrolled patients, 227 (97%) were screened at diagnosis. A molecular marker (MM) was found in 51%. Patients with an MM were monitored at 8 subsequent times. Of the 675 expected follow-up samples, 83% were analyzed. Conversion to PCR negativity predicted better progression-free survival (PFS) at all post-treatment times (eg, end of therapy: 3-year PFS, 72% vs 39%; P < .007). MRD was predictive in both maintenance (83% vs 60%; P < .007) and observation (71% vs 50%; P < .001) groups. PCR positivity at the end of induction was an independent adverse predictor (hazard ratio, 3.1; 95% confidence interval, 1.36-7.07). MRD is a powerful independent outcome predictor in FL patients who receive rituximab-intensive programs, suggesting a need to investigate its value for decision-making. This trial was registered at www.clinicaltrial.gov as #NCT01144364. © 2013 by The American Society of Hematology.
122
23
3759
3766
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program / Marco, Ladetto; Chiara, Lobetti-Bodoni; Barbara, Mantoan; Manuela, Ceccarelli; Carola, Boccomini; Elisa, Genuardi; Annalisa, Chiappella; Baldini, Luca; Giuseppe, Rossi; Alessandro, Pulsoni; Francesco Di Raimondo, ; Luigi, Rigacci; Antonello, Pinto; Sara, Galimberti; Bari, Alessia; Delia, Rota-Scalabrini; Angela, Ferrari; Francesco, Zaja; Andrea, Gallamini; Giorgina, Specchia; Pellegrino, Musto; Francesca Gaia Rossi, ; Enrica, Gamba; Andrea Evangelista and Umberto Vitolo for the Fondazione Italiana Linfomi, ; Collaborators: Lobetti-Bodoni, C; Mantoan, B; Genuardi, E; Boccadoro, M; Ladetto, M; Ciccone, G; Evangelista, A; Ceccarelli, M; Boccomini, C; Chiappella, A; Botto, B; Orsucci, L; Vitolo, U; Goldaniga, M; Rossi, Fg; Baldini, L; Bottelli, C; Tucci, Angelo Carmelo; Rossi, G; Pulsoni, A; De Angelis, F; RUSSO ERMOLLI, Elda; Martelli, M; Foà, R; Di Raimondo, F; Chiarenza, Antonino; Rigacci, L; Puccini, B; Bosi, A; Pinto, Alessandra; Petrini, Marino; Galimberti, S; Bari, A; Sacchi, S; Federico, M; Rota-Scalabrini, D; Aglietta, M; Ferrari, A; Alvarez De Celis, I; Merli, F; Zaja, F; Fanin, R; Castellino, C; Gallamini, A; Parvis, G; Saglio, G; Perrone, T; Specchia, G; Musto, P; Gamba, E; Corradini, P; Pogliani, Em; Liberati, Am; Leone, G; Patti, C; Fioritoni, G; Rusconi, C; Morra, E; Tonso, A; Cabras, G; Angelucci, E; Rossi, A; Rambaldi, A; Cortelazzo, S; Morandi, S; Lanza, F; Pizzolo, G; Amadori, S; Zinzani, Pl; Stelitano, C; Nobile, F. - In: BLOOD. - ISSN 0006-4971. - 122:23(2013), pp. 3759-3766. [10.1182/blood-2013-06-507319]
Marco, Ladetto; Chiara, Lobetti-Bodoni; Barbara, Mantoan; Manuela, Ceccarelli; Carola, Boccomini; Elisa, Genuardi; Annalisa, Chiappella; Baldini, Luca; Giuseppe, Rossi; Alessandro, Pulsoni; Francesco Di Raimondo, ; Luigi, Rigacci; Antonello, Pinto; Sara, Galimberti; Bari, Alessia; Delia, Rota-Scalabrini; Angela, Ferrari; Francesco, Zaja; Andrea, Gallamini; Giorgina, Specchia; Pellegrino, Musto; Francesca Gaia Rossi, ; Enrica, Gamba; Andrea Evangelista and Umberto Vitolo for the Fondazione Italiana Linfomi, ; Collaborators: Lobetti-Bodoni, C; Mantoan, B; Genuardi, E; Boccadoro, M; Ladetto, M; Ciccone, G; Evangelista, A; Ceccarelli, M; Boccomini, C; Chiappella, A; Botto, B; Orsucci, L; Vitolo, U; Goldaniga, M; Rossi, Fg; Baldini, L; Bottelli, C; Tucci, Angelo Carmelo; Rossi, G; Pulsoni, A; De Angelis, F; RUSSO ERMOLLI, Elda; Martelli, M; Foà, R; Di Raimondo, F; Chiarenza, Antonino; Rigacci, L; Puccini, B; Bosi, A; Pinto, Alessandra; Petrini, Marino; Galimberti, S; Bari, A; Sacchi, S; Federico, M; Rota-Scalabrini, D; Aglietta, M; Ferrari, A; Alvarez De Celis, I; Merli, F; Zaja, F; Fanin, R; Castellino, C; Gallamini, A; Parvis, G; Saglio, G; Perrone, T; Specchia, G; Musto, P; Gamba, E; Corradini, P; Pogliani, Em; Liberati, Am; Leone, G; Patti, C; Fioritoni, G; Rusconi, C; Morra, E; Tonso, A; Cabras, G; Angelucci, E; Rossi, A; Rambaldi, A; Cortelazzo, S; Morandi, S; Lanza, F; Pizzolo, G; Amadori, S; Zinzani, Pl; Stelitano, C; Nobile, F
File in questo prodotto:
File Dimensione Formato  
23.pdf

non disponibili

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 843.7 kB
Formato Adobe PDF
843.7 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1148609
Citazioni
  • ???jsp.display-item.citation.pmc??? 23
  • Scopus 64
  • ???jsp.display-item.citation.isi??? 62
social impact